Cue Biopharma Business Summary

Cue Biopharma, Inc. (CUE) is a clinical-stage biopharmaceutical company that generates revenue exclusively through strategic collaboration and licensing agreements, selling intellectual property access and development services rather than commercial products. Its primary business segments are focused on oncology and autoimmune/inflammatory diseases, utilizing its proprietary Immuno-STAT platform to develop injectable biologics that selectively modulate disease-specific T cells. Key revenue drivers include a high-profile partnership with Boehringer Ingelheim for the CUE-501 program and a 2025 "Seed-and-Boost" cell therapy collaboration with ImmunoScape. Within the competitive landscape, Cue Biopharma operates as a small-cap innovator alongside direct peers such as Aura Biosciences, Cardiff Oncology, and Coya Therapeutics, distinguishing itself through a platform designed to restore immune homeostasis without the systemic toxicities typical of broad-spectrum immunotherapies. The company is led by President and CEO Usman “Oz” Azam, M.D., who joined in September 2025 bringing deep pedigree from Novartis, where he launched the first-ever FDA-approved CAR-T therapy, and previous leadership roles at Pfizer and Johnson & Johnson. In February 2026, the executive team was further strengthened by the appointment of Lucinda Warren as Chief Financial and Business Officer, a 30-year industry veteran formerly of Johnson & Johnson and Janssen. The company was co-founded by Rodolfo Chaparro and Ron Seidel, with its scientific foundations rooted in research from the Albert Einstein College of Medicine. Notable institutional backing includes MDB Capital Holdings and Bleichroeder LP, while the Board of Directors is chaired by Frank Morich, M.D., Ph.D., a former executive at Takeda Pharmaceuticals and Bayer.